Clinical Trial Update: Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 study funded by GlaxoSmithKline evaluating a second-line therapy for potentially platinum-sensitive relapsed ovarian cancer; results were posted in 2009…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Snippet

Sponsor: GlaxoSmithKline | Conditions: Ovarian Cancer, Neoplasms, Ovarian | Phase 2 | Status: COMPLETED | Results posted: 2009-11-26